Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:VLON

Vallon Pharmaceuticals (VLON) Stock Price, News & Analysis

Vallon Pharmaceuticals logo

About Vallon Pharmaceuticals Stock (NASDAQ:VLON)

Advanced Chart

Key Stats

Today's Range
$0.84
$0.92
50-Day Range
$0.27
$2.87
52-Week Range
$0.21
$12.92
Volume
338,927 shs
Average Volume
5.78 million shs
Market Capitalization
$12.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

Receive VLON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vallon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VLON Stock News Headlines

Questcor Pharmaceuticals,
Buy this Stock before Trump Takes Office!
We're issuing an urgent "buy alert" on a little-known "AI company" set to SOAR under this new administration. And it's not just because it hit a critical "buy now" price.
See More Headlines

VLON Stock Analysis - Frequently Asked Questions

Vallon Pharmaceuticals's stock reverse split on Monday, April 24th 2023. The 1-30 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Vallon Pharmaceuticals (VLON) raised $15 million in an initial public offering on Wednesday, February 10th 2021. The company issued 1,700,000 shares at $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vallon Pharmaceuticals investors own include Meta Platforms (META), Alkaline Water (WTER), SoFi Technologies (SOFI), Exro Technologies (EXROF), AMC Entertainment (AMC), Alpha Lithium (APHLF) and Avino Silver & Gold Mines (ASM).

Company Calendar

Today
1/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VLON
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Net Income
$-7,020,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$100,000.00
Book Value
$0.18 per share

Miscellaneous

Free Float
8,453,000
Market Cap
$12.23 million
Optionable
Not Optionable
Beta
-1.14
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:VLON) was last updated on 1/6/2025 by MarketBeat.com Staff
From Our Partners